首页> 外文期刊>Archivio Italiano di Urologia e Andrologia >“In-bore” MRI prostate biopsy is a safe preoperative clinical tool to exclude significant prostate cancer in symptomatic patients with benign prostatic obstruction before transurethral laser enucleation
【24h】

“In-bore” MRI prostate biopsy is a safe preoperative clinical tool to exclude significant prostate cancer in symptomatic patients with benign prostatic obstruction before transurethral laser enucleation

机译:“孔内” MRI前列腺活检是一种安全的术前临床工具,可在经尿道激光摘除术之前排除有症状的良性前列腺梗阻患者的重大前列腺癌

获取原文
           

摘要

Introduction: Purpose of our study was to investigate the role of a negative in-bore MRI-guided biopsy (MRI-GB) in comparison to a negative multiparametric prostate MRI (mpMRI) and a contextual negative transrectal ultrasound guided biopsy of the prostate with regard to incidental prostate cancer findings in the surgical specimen of men who underwent to Holmium Laser enucleation of prostate (HoLEP) with a preoperative suspicion of prostate cancer. Materials and methods: Data of 117 of symptomatic patients for bladder outflow obstruction who subsequently underwent to HoLEP was retrospectively analyzed form a multicentric database. All patients had a raised serum PSA and/or an abnormal digital rectal examination (DRE) with a pre-interventional mpMRI. Prostate cancer was excluded either with an en-bore MRI-GB (group "IN-BORE MRI-GB" n = 57) in case of a suspect area at the mpMRI or with a standard biopsy (group "mpMRI + TRUS-GB" n = 60) in case of a negative mpMRI. Preoperative characteristic surgical and histological outcomes were analyzed. Univariate and multivariate logistic regression model was performed to investigate independent predictors of incidental Prostate Cancer (iPCa). Results: Both groups presented moderate to severe lower tract urinary symptoms: median IPSS was 19 (IQR: 17.0-22.0) in the IN-BORE MRI-GB group and 20 (IQR: 17.5-22.0) in the mpMRI + TRUS-GB (p = 0.71). No statistically significant difference was found between the two groups besides total prostate volume with 68 cc (IQR: 58.0-97.0) in the IN-BORE MRI-GB group and 84 cc (IQR: 70.0-115.0) in the mpMRI + TRU-GB group (p = 0.01) No differences were registered in surgical time, removed tissue, catheterization time, hospital stay and complications rate. No different rates (p = 0.50) of iPCa were found in the IN-BORE MRI-GB group (14%) in comparison with mpMRI + TRUS-GB group (10 %); pT stage and ISUP Grade Group in iPCa stratification were comparable between the two groups. In multivariate analysis a statistically significant correlation with age as an independent predictive factor of iPCa was found (OR 1.14; 95% CI: 1.02-1.27; p = 0.02) while no correlations were revealed with PSA (OR 1.12; 95% CI: 0.99-1.28; p = 0.08) and a negative in-bore MRI-GB (OR 1.72; 95% CI: 0.51-5.77; p = 0.37). Conclusions: Including a mpMRI and an eventual in-bore MRIGB represents a novel clinical approach before surgery in patients with symptomatic obstruction with a concomitant suspicion of PCa, leading to low rate of iPCa and avoiding unnecessary standard TRUS-GB biopsies.
机译:简介:我们的研究目的是研究阴性的孔内MRI引导活检(MRI-GB)与阴性的多参数前列腺MRI(mpMRI)和上下文阴性的经直肠超声引导的前列腺活检相比的作用接受了Hol激光前列腺摘除术(HoLEP)并在术前怀疑患有前列腺癌的男性的手术标本中发现了偶然的前列腺癌发现。材料和方法:回顾性分析多中心数据库中117例随后接受HoLEP治疗的有症状的膀胱外流梗阻患者的数据。所有患者的术前mpMRI血清PSA升高和/或直肠指检异常(DRE)。如果在mpMRI处有可疑区域,则通过内镜MRI-GB(“ IN-BORE MRI-GB”组n = 57)或标准活检(“ mpMRI + TRUS-GB”组)排除前列腺癌如果mpMRI阴性,则n = 60)。术前特征性手术和组织学结果进行了分析。进行单因素和多因素logistic回归模型以研究偶然前列腺癌(iPCa)的独立预测因子。结果:两组均出现中度至重度下尿路症状:IN-BORE MRI-GB组的中位IPSS为19(IQR:17.0-22.0),而mpMRI + TRUS-GB组的中位IPSS为20(IQR:17.5-22.0)( p = 0.71)。除总前列腺体积为IN-BORE MRI-GB组的68 cc(IQR:58.0-97.0)和mpMRI + TRU-GB的84 cc(IQR:70.0-115.0)外,两组之间均无统计学差异。 (p = 0.01)组的手术时间,切除的组织,导管插入时间,住院时间和并发症发生率均无差异。与mpMRI + TRUS-GB组(10%)相比,IN-BORE MRI-GB组(14%)未发现iPCa的不同发生率(p = 0.50)。在iPCa分层中的pT分期和ISUP分级组在两组之间具有可比性。在多变量分析中,发现与年龄相关的统计学显着相关性(iPCa的独立预测因子)(OR 1.14; 95%CI:1.02-1.27; p = 0.02),而与PSA无关(OR 1.12; 95%CI:0.99)。 -1.28; p = 0.08)和阴性MRI-GB(OR 1.72; 95%CI:0.51-5.77; p = 0.37)。结论:包括mpMRI和最终孔内MRIGB代表有症状的梗阻伴有PCa怀疑的患者在手术前的一种新的临床方法,从而导致iPCa的发生率低并避免了不必要的标准TRUS-GB活检。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号